OUI Medical Pitch 21-2-2023 copy.pptx
•
0 likes•11 views
Oui Medical Inc has developed a single-use, portable scope that allows doctors to visually examine the abdominal cavity using local anesthesia, providing a less expensive and less invasive alternative to traditional laparoscopy. The device addresses a $4 billion market and could enable 500,000 additional abdominal procedures annually in the US. Oui is seeking $7 million in funding to complete clinical studies, obtain FDA approval, and launch the product.
Report
Share
Report
Share
Recommended
PITCH OUI Medical .pdf
The document discusses a new medical device company called Oui Medical Inc. that is developing a portable, single-use scope to allow doctors to examine the abdominal cavity using local anesthesia rather than surgery. Currently, examining the abdomen requires an invasive surgery with general anesthesia that is painful, costly, and inconvenient. Oui Medical's solution is a world's first scope that can peek inside the abdomen using a minimally invasive ambulatory procedure with local anesthesia, making it painless and convenient for just $6,000 compared to $50,000 for surgery. The company is seeking $7 million in funding to complete product development and clinical studies to bring the product to market.
Fortis oncology nanomedicine solutions
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Fortis Oncology - Nanomedicine Solutions
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
OUI Medical.pptx
This document introduces a new peritoneoscope device created by a team with expertise in engineering, medicine, and business. The device allows minimally invasive abdominal examinations under local anesthesia as an outpatient procedure, avoiding costs and risks of laparoscopy. It addresses an unmet need in several medical specialties. The team's plan is to develop the device with partners, obtain regulatory approval, and either market the product themselves or license it to a larger medical company. They provide a timeline and budget of $7 million to bring the device to market over 2 years.
Medtech & pharma sector strategy - 6 months of progress
A summary of 46 actions undertaken by the Victorian Government in the six months since the Medtech and Pharmaceuticals Sector strategy was released in March 2016
Data Virtualization Modernizes Biobanking
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
The Canadian Clinical Trials Asset Map (CCTAM) - Shurjeel H Choudhri and Alis...
The Canadian Clinical Trials Asset Map (CCTAM) is an initiative to create an online, searchable database of Canadian clinical research capabilities. The objectives are to improve capacity for clinical research in Canada and position Canada as an attractive destination for clinical trials. Significant progress has been made in developing CCTAM, which will leverage existing asset maps and include comprehensive data on investigators, sites, and research organizations. Once complete, CCTAM aims to be a one-stop tool to support clinical research planning in Canada.
apidays LIVE Australia 2021 - APIs enable global collaborations and accelerat...
apidays LIVE Australia 2021 - Accelerating Digital
September 15 & 16, 2021
Locknote: APIs enable global collaborations and accelerate health and medical research
Dr. Denis Bauer, Head Cloud Computing Bioinformatics at CSIRO
Recommended
PITCH OUI Medical .pdf
The document discusses a new medical device company called Oui Medical Inc. that is developing a portable, single-use scope to allow doctors to examine the abdominal cavity using local anesthesia rather than surgery. Currently, examining the abdomen requires an invasive surgery with general anesthesia that is painful, costly, and inconvenient. Oui Medical's solution is a world's first scope that can peek inside the abdomen using a minimally invasive ambulatory procedure with local anesthesia, making it painless and convenient for just $6,000 compared to $50,000 for surgery. The company is seeking $7 million in funding to complete product development and clinical studies to bring the product to market.
Fortis oncology nanomedicine solutions
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
Fortis Oncology - Nanomedicine Solutions
Targeted nanoparticle tumor ablation. Multi-walled Carbon Nanotubes (MWCNT) are designed with internal antennae tuned to a specific Near Infrared (NIR) laser frequency, which when activated, oscillate at high speeds, generating thermal energy (heat) sufficient to cause cell apoptosis. Using targeting probes, the MWCNT only seek out, attach to, and within, specific cancer cells. The NIR laser is non-invasive, and does not injure the skin. The MWCNT can also be conjugated with probes for very specific imaging for diagnostics purposes using existing MRI technology.
OUI Medical.pptx
This document introduces a new peritoneoscope device created by a team with expertise in engineering, medicine, and business. The device allows minimally invasive abdominal examinations under local anesthesia as an outpatient procedure, avoiding costs and risks of laparoscopy. It addresses an unmet need in several medical specialties. The team's plan is to develop the device with partners, obtain regulatory approval, and either market the product themselves or license it to a larger medical company. They provide a timeline and budget of $7 million to bring the device to market over 2 years.
Medtech & pharma sector strategy - 6 months of progress
A summary of 46 actions undertaken by the Victorian Government in the six months since the Medtech and Pharmaceuticals Sector strategy was released in March 2016
Data Virtualization Modernizes Biobanking
Access the webinar: http://goo.gl/p08pTz
These slides were presented in a webinar by Denodo in collaboration with BioStorage Technologies and Indiana Clinical and Translational Sciences Institute and Regenstrief Institute.
BioStorage Technologies, Inc., Indiana Clinical and Translational Sciences Institute, and Regenstrief Institute (CTSI) have joined Denodo to talk about the important role of technological advancements, such as data virtualization, in advancing biospecimen research.
By watching this webinar, you can gain insight into best practices around the integration of biospecimen and research data as well as technology solutions that provide consolidated views and rapid conversions of this data into valuable business insights. You will also learn how data virtualization can assist with the integration of data residing in heterogeneous repositories and can securely deliver aggregated data in real-time.
The Canadian Clinical Trials Asset Map (CCTAM) - Shurjeel H Choudhri and Alis...
The Canadian Clinical Trials Asset Map (CCTAM) is an initiative to create an online, searchable database of Canadian clinical research capabilities. The objectives are to improve capacity for clinical research in Canada and position Canada as an attractive destination for clinical trials. Significant progress has been made in developing CCTAM, which will leverage existing asset maps and include comprehensive data on investigators, sites, and research organizations. Once complete, CCTAM aims to be a one-stop tool to support clinical research planning in Canada.
apidays LIVE Australia 2021 - APIs enable global collaborations and accelerat...
apidays LIVE Australia 2021 - Accelerating Digital
September 15 & 16, 2021
Locknote: APIs enable global collaborations and accelerate health and medical research
Dr. Denis Bauer, Head Cloud Computing Bioinformatics at CSIRO
clinicaltrials.dr.surinder.pptx
The document discusses India's growing attractiveness as a destination for clinical trials. It notes that India has a large patient pool, low costs, and a growing clinical research industry. Regulatory reforms have made the environment more favorable and increased India's competitiveness. The number of clinical trials and participating organizations in India has increased significantly in recent years. However, the regulatory approval process can still be improved by establishing timelines and a single window clearance system. Overall, India aims to become a premier global destination for clinical research.
CORBEL BBMRI-ERIC QM webinar slides
Increasing demand and the use of high-quality samples, data and services place biobanks at the center of basic and applied research. The BBMRI-ERIC Quality Management Service (BBMRI.QM) is designed to help biobanks and researchers meet the highest quality standards for their research and meet the needs of their clients. This webinar will give you an insight into the service portfolio of BBMRI.QM and an overview of relevant European and international standards useful for research on human specimens.
CORBEL (http://www.corbel-project.eu) is an initiative of eleven new biological and medical research infrastructures (BMS RIs), which together will create a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. CORBEL will boost the efficiency, productivity and impact of European biomedical research.
This webinar took place on 6th December 2018 and is part of the CORBEL webinar series. A recording of the webinar is available through the CORBEL website:
https://www.corbel-project.eu/webinars/bbmri-eric-quality-management-services.html
For previous and upcoming CORBEL webinars see:
http://www.corbel-project.eu/webinars
Roundup of This Year's AACC Meeting in Atlanta
Major developments in point-of-care (POC) testing were highlighted at the 2015 American Association of Clinical Chemistry Annual Meeting:
1) Several companies announced new POC devices, including a low-cost, battery-powered molecular diagnostics platform from Cepheid and a smartphone-based chlamydia test.
2) Existing POC tests for influenza, diabetes, kidney disease, liver disease, and pregnancy from companies like Alere, DiaSys Diagnostics, and Abbott were demonstrated.
3) The large POC diagnostics market, estimated at $17 billion globally, was a focus for many exhibitors given the potential for rapid results at the point of care.
BioTime Investor Presentation 2016
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
Innovative CEA Testing Technologies and Emerging Markets
The 250-page report analyzes the CEA testing market in several countries and forecasts growth over 5 and 10 years. It examines technologies like DNA probes, biochips, monoclonal antibodies, and automated analyzers used for CEA testing. The report profiles major suppliers and recent entrants developing innovative CEA testing technologies and products. It also identifies alternative market strategies and potential barriers to entry. The cancer diagnostics market is poised for strong growth as technological breakthroughs enable new ways to diagnose and treat cancer at the genetic level.
InSitu Biologics Corporate
This document summarizes a presentation by InSitu Biologics given in April 2019. It introduces the founders and history of the company, which was incorporated in 2014 and develops drug-eluting hydrogel technologies licensed from the Cleveland Clinic Foundation. It provides an overview of their lead product AnestaGel, a bupivacaine-eluting hydrogel for post-operative pain management, which has shown longer-lasting analgesic effects than competitors in pre-clinical studies. The company is preparing for a Phase 1 safety trial and manufacturing scale-up to target the large non-opioid pain market. It also lists other potential medical applications of their tunable hydrogel platform and strategic focus on proving safety with Anest
Cancer Genetics Investor Deck
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
CARTaGENE - Hacking Health Café
The CARTaGENE project was created to facilitate innovation and research projects while ensuring the longitudinal mandate of its cohort. It aims to advance population health knowledge by reducing research costs, improving disease prevention, and enabling personalized medicine. The project has recruited over 42,000 participants from Quebec and collected blood samples, physical measurements, and questionnaires to create a biobank. It provides open access to de-identified data and biosamples to approved researchers studying human health.
Bio Derm Press Kit
The document discusses new technologies for male bladder control and the limitations of current methods. It introduces Liberty as the first new male bladder control method in 50 years. Current methods like diapers, catheters, and condom catheters increase risks of infection, skin damage, and social stigma. Liberty aims to provide a safer, simpler solution for bladder control.
Aiforia - Pörssisijoittajan viikko 12.9.2023.pptx
Pörssisijoittajan viikko.
Tekoälyllä tehokkuutta ja täsmällisyyttä
kudosdiagnostiikkaan.
Kasvu ja yrityskaupat.
BioSculpture Investor Presentation Highlights (8 1-17, public)
8/1/17 Public update of BioSculpture Technology, Inc. Business Plan and Corporate Capsule for Investors
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reduced
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reducedRobert Cucin MD JD FACS
BioSculpture Technology, Inc. Investor Presentation Highlights 9/10/16 - Qualified Tier 2 Reg. A OfferingInnovative PSA Testing Technologies and Emerging Markets
The 249-page report analyzes the PSA testing market in the US, Europe, and Japan through 2022. It details market sizes, growth forecasts, sales projections by country and supplier. The report examines current and emerging testing technologies like monoclonal antibodies, immunoassays, molecular diagnostics, and their applications. It also identifies alternative market strategies, barriers to entry, and profiles major industry suppliers. The cancer diagnostics market is poised for rapid expansion driven by technological breakthroughs in tumor detection and treatment.
Innovative AFP Testing Technologies and Emerging Markets
This 248-page report provides a detailed analysis of the alpha-fetoprotein testing market in several countries and forecasts sales and market shares for major suppliers over the next 5-10 years. It examines current and emerging testing technologies like monoclonal antibodies, immunoassays, molecular diagnostics, and flow cytometry. The report also identifies alternative market entry strategies, barriers to entry, and provides competitive profiles of major industry players.
NIHR Roadshow for Medical Technology SMEs
Presentations from the NIHR Roadshow for Medical Technology SMEs on Thursday 1 March 2018 at Sci-Tech Daresbury.
Scope On Cdm In India Dr S K Gupta
1) India is emerging as an attractive destination for outsourcing clinical research due to its large patient pools, low costs, and trained workforce.
2) The clinical research industry in India has grown significantly in recent years and is expected to grow from $100 million in 2004 to over $300 million by 2010.
3) India offers many advantages over other countries for clinical trials including lower costs, treatment-naïve patients, and investigators trained in Western practices.
Stratified Medicines Innovation Platform
EuroBioForum 2012 | 18 April 2012
Presentation by Graham Bell, Lead Specialist Stratified Medicine, Technology Strategy Board
Narvitas Presentation March 2015
- Narvitas Medical Devices develops proprietary medical devices to improve laparoscopic and epidural procedures.
- Their first product, LapDome, provides safer and faster abdominal access during laparoscopic surgery compared to current Veress needle methods, addressing a $15 million market that is growing 8.3% annually.
- The management team has experience in medical device companies and regulatory approval processes. Financial projections estimate positive EBITDA by 2016 and growing profits through 2017 as the company expands into new markets.
IMERA Business Plan Sep 2023 Enterprise AI Event.pptx.pdf
IMERA.AI has developed an AI solution to analyze medical imaging like X-rays to address the shortage of radiologists. Their solution has received regulatory approval in the UK and they are working to expand to other markets. The business plan outlines their product, which can currently analyze musculoskeletal X-rays, as well as their roadmap to add new capabilities and regions over the next few years. It also details their management team, achievements, and strategy to engage customers and drive revenue.
Innovation in medical device and diagnostic industry at India Leadership Conc...
Conceptualized& instituted in the year by India’s most respected journalist Satya Brahma, India Leadership Conclave Awards are are meant to highlight & celebrate those individuals & companies who’ve ascended to the top of their business against all odds. Currently celebrating its 9th successful annual editions, iconic figures such as Ratata Tata, MukeshAmbani, Naresh Goyal, Narayan Murthy, Shiv Nadar,SudhaMurthy,Priyanka Chopra, Manish Malhotra, Neeta Lulla, Late Yash Chopra, Govinda, Rani Mukerjee, Sushimita Sen, Karishma Kapoor are some of its proud recipients. Being India’s most iconic leadership awards having a tremendous impact on the credibility of the Group, India Leadership Conclave jury takes every steps to ensure fair, credible & independent selection process,.The nomination categories, eligibility criteria, selection process & evaluation criteria constitute the core areas of research. Public voting constitutes its biggest parameters. Physical interviews by Network 7 Media Group Journalists on ground on each nominee are conducted followed by Jury’s strong analytical verdict. The set of awards developed by the Board Members of the Network 7 Media Group is to propel the talent engine & encourage, motivate the innovative entrepreneurs. These leadership awards are aimed at empowering the leaders who think differently.This recognition voted by the people of india& subsequent by Jury Board reflect the Winner’s remarkable achievement & accomplishments as a leader of substance driven by passion, initiative & commitment to deliver excellence. India Leadership Conclave Awards are special as we don’t follow any traditional guidelines, defy conventions & crown winners based on innovations, merit & competence. Our decision is based on number of factors which are transparent, robust & driven by extensive research.
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24
More Related Content
Similar to OUI Medical Pitch 21-2-2023 copy.pptx
clinicaltrials.dr.surinder.pptx
The document discusses India's growing attractiveness as a destination for clinical trials. It notes that India has a large patient pool, low costs, and a growing clinical research industry. Regulatory reforms have made the environment more favorable and increased India's competitiveness. The number of clinical trials and participating organizations in India has increased significantly in recent years. However, the regulatory approval process can still be improved by establishing timelines and a single window clearance system. Overall, India aims to become a premier global destination for clinical research.
CORBEL BBMRI-ERIC QM webinar slides
Increasing demand and the use of high-quality samples, data and services place biobanks at the center of basic and applied research. The BBMRI-ERIC Quality Management Service (BBMRI.QM) is designed to help biobanks and researchers meet the highest quality standards for their research and meet the needs of their clients. This webinar will give you an insight into the service portfolio of BBMRI.QM and an overview of relevant European and international standards useful for research on human specimens.
CORBEL (http://www.corbel-project.eu) is an initiative of eleven new biological and medical research infrastructures (BMS RIs), which together will create a platform for harmonised user access to biological and medical technologies, biological samples and data services required by cutting-edge biomedical research. CORBEL will boost the efficiency, productivity and impact of European biomedical research.
This webinar took place on 6th December 2018 and is part of the CORBEL webinar series. A recording of the webinar is available through the CORBEL website:
https://www.corbel-project.eu/webinars/bbmri-eric-quality-management-services.html
For previous and upcoming CORBEL webinars see:
http://www.corbel-project.eu/webinars
Roundup of This Year's AACC Meeting in Atlanta
Major developments in point-of-care (POC) testing were highlighted at the 2015 American Association of Clinical Chemistry Annual Meeting:
1) Several companies announced new POC devices, including a low-cost, battery-powered molecular diagnostics platform from Cepheid and a smartphone-based chlamydia test.
2) Existing POC tests for influenza, diabetes, kidney disease, liver disease, and pregnancy from companies like Alere, DiaSys Diagnostics, and Abbott were demonstrated.
3) The large POC diagnostics market, estimated at $17 billion globally, was a focus for many exhibitors given the potential for rapid results at the point of care.
BioTime Investor Presentation 2016
The document discusses BioTime, Inc., a biotechnology company leading the regenerative medicine revolution. It summarizes BioTime's expertise in pluripotent stem cells and its focus on advancing two clinical programs - Renevia for facial aesthetics and OpRegen for dry age-related macular degeneration. It outlines upcoming milestones for these programs in 2016-2017, and how BioTime is unlocking value from its ownership stakes in public subsidiaries Asterias and OncoCyte, which are applying BioTime's stem cell technologies to therapies for conditions with high unmet medical need.
Innovative CEA Testing Technologies and Emerging Markets
The 250-page report analyzes the CEA testing market in several countries and forecasts growth over 5 and 10 years. It examines technologies like DNA probes, biochips, monoclonal antibodies, and automated analyzers used for CEA testing. The report profiles major suppliers and recent entrants developing innovative CEA testing technologies and products. It also identifies alternative market strategies and potential barriers to entry. The cancer diagnostics market is poised for strong growth as technological breakthroughs enable new ways to diagnose and treat cancer at the genetic level.
InSitu Biologics Corporate
This document summarizes a presentation by InSitu Biologics given in April 2019. It introduces the founders and history of the company, which was incorporated in 2014 and develops drug-eluting hydrogel technologies licensed from the Cleveland Clinic Foundation. It provides an overview of their lead product AnestaGel, a bupivacaine-eluting hydrogel for post-operative pain management, which has shown longer-lasting analgesic effects than competitors in pre-clinical studies. The company is preparing for a Phase 1 safety trial and manufacturing scale-up to target the large non-opioid pain market. It also lists other potential medical applications of their tunable hydrogel platform and strategic focus on proving safety with Anest
Cancer Genetics Investor Deck
This document provides an overview of Cancer Genetics, Inc. (CGI) and their focus on being an oncology diagnostics partner from bench to bedside. Some key points:
- CGI utilizes targeted acquisitions and collaborations with research institutions to expand their testing capabilities and global footprint.
- They have a proprietary portfolio of over 20 genomic tests and panels focused on cancers like blood cancers, lymphomas, lung cancer, and solid tumors.
- CGI partners with leading biopharma companies, supporting over 120 clinical trials with testing and services. They have contracts with 8 of the top 10 biopharma companies.
CARTaGENE - Hacking Health Café
The CARTaGENE project was created to facilitate innovation and research projects while ensuring the longitudinal mandate of its cohort. It aims to advance population health knowledge by reducing research costs, improving disease prevention, and enabling personalized medicine. The project has recruited over 42,000 participants from Quebec and collected blood samples, physical measurements, and questionnaires to create a biobank. It provides open access to de-identified data and biosamples to approved researchers studying human health.
Bio Derm Press Kit
The document discusses new technologies for male bladder control and the limitations of current methods. It introduces Liberty as the first new male bladder control method in 50 years. Current methods like diapers, catheters, and condom catheters increase risks of infection, skin damage, and social stigma. Liberty aims to provide a safer, simpler solution for bladder control.
Aiforia - Pörssisijoittajan viikko 12.9.2023.pptx
Pörssisijoittajan viikko.
Tekoälyllä tehokkuutta ja täsmällisyyttä
kudosdiagnostiikkaan.
Kasvu ja yrityskaupat.
BioSculpture Investor Presentation Highlights (8 1-17, public)
8/1/17 Public update of BioSculpture Technology, Inc. Business Plan and Corporate Capsule for Investors
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reduced
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reducedRobert Cucin MD JD FACS
BioSculpture Technology, Inc. Investor Presentation Highlights 9/10/16 - Qualified Tier 2 Reg. A OfferingInnovative PSA Testing Technologies and Emerging Markets
The 249-page report analyzes the PSA testing market in the US, Europe, and Japan through 2022. It details market sizes, growth forecasts, sales projections by country and supplier. The report examines current and emerging testing technologies like monoclonal antibodies, immunoassays, molecular diagnostics, and their applications. It also identifies alternative market strategies, barriers to entry, and profiles major industry suppliers. The cancer diagnostics market is poised for rapid expansion driven by technological breakthroughs in tumor detection and treatment.
Innovative AFP Testing Technologies and Emerging Markets
This 248-page report provides a detailed analysis of the alpha-fetoprotein testing market in several countries and forecasts sales and market shares for major suppliers over the next 5-10 years. It examines current and emerging testing technologies like monoclonal antibodies, immunoassays, molecular diagnostics, and flow cytometry. The report also identifies alternative market entry strategies, barriers to entry, and provides competitive profiles of major industry players.
NIHR Roadshow for Medical Technology SMEs
Presentations from the NIHR Roadshow for Medical Technology SMEs on Thursday 1 March 2018 at Sci-Tech Daresbury.
Scope On Cdm In India Dr S K Gupta
1) India is emerging as an attractive destination for outsourcing clinical research due to its large patient pools, low costs, and trained workforce.
2) The clinical research industry in India has grown significantly in recent years and is expected to grow from $100 million in 2004 to over $300 million by 2010.
3) India offers many advantages over other countries for clinical trials including lower costs, treatment-naïve patients, and investigators trained in Western practices.
Stratified Medicines Innovation Platform
EuroBioForum 2012 | 18 April 2012
Presentation by Graham Bell, Lead Specialist Stratified Medicine, Technology Strategy Board
Narvitas Presentation March 2015
- Narvitas Medical Devices develops proprietary medical devices to improve laparoscopic and epidural procedures.
- Their first product, LapDome, provides safer and faster abdominal access during laparoscopic surgery compared to current Veress needle methods, addressing a $15 million market that is growing 8.3% annually.
- The management team has experience in medical device companies and regulatory approval processes. Financial projections estimate positive EBITDA by 2016 and growing profits through 2017 as the company expands into new markets.
IMERA Business Plan Sep 2023 Enterprise AI Event.pptx.pdf
IMERA.AI has developed an AI solution to analyze medical imaging like X-rays to address the shortage of radiologists. Their solution has received regulatory approval in the UK and they are working to expand to other markets. The business plan outlines their product, which can currently analyze musculoskeletal X-rays, as well as their roadmap to add new capabilities and regions over the next few years. It also details their management team, achievements, and strategy to engage customers and drive revenue.
Innovation in medical device and diagnostic industry at India Leadership Conc...
Conceptualized& instituted in the year by India’s most respected journalist Satya Brahma, India Leadership Conclave Awards are are meant to highlight & celebrate those individuals & companies who’ve ascended to the top of their business against all odds. Currently celebrating its 9th successful annual editions, iconic figures such as Ratata Tata, MukeshAmbani, Naresh Goyal, Narayan Murthy, Shiv Nadar,SudhaMurthy,Priyanka Chopra, Manish Malhotra, Neeta Lulla, Late Yash Chopra, Govinda, Rani Mukerjee, Sushimita Sen, Karishma Kapoor are some of its proud recipients. Being India’s most iconic leadership awards having a tremendous impact on the credibility of the Group, India Leadership Conclave jury takes every steps to ensure fair, credible & independent selection process,.The nomination categories, eligibility criteria, selection process & evaluation criteria constitute the core areas of research. Public voting constitutes its biggest parameters. Physical interviews by Network 7 Media Group Journalists on ground on each nominee are conducted followed by Jury’s strong analytical verdict. The set of awards developed by the Board Members of the Network 7 Media Group is to propel the talent engine & encourage, motivate the innovative entrepreneurs. These leadership awards are aimed at empowering the leaders who think differently.This recognition voted by the people of india& subsequent by Jury Board reflect the Winner’s remarkable achievement & accomplishments as a leader of substance driven by passion, initiative & commitment to deliver excellence. India Leadership Conclave Awards are special as we don’t follow any traditional guidelines, defy conventions & crown winners based on innovations, merit & competence. Our decision is based on number of factors which are transparent, robust & driven by extensive research.
Similar to OUI Medical Pitch 21-2-2023 copy.pptx (20)
Innovative CEA Testing Technologies and Emerging Markets
Innovative CEA Testing Technologies and Emerging Markets
BioSculpture Investor Presentation Highlights (8 1-17, public)
BioSculpture Investor Presentation Highlights (8 1-17, public)
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reduced
BioSculpture Technology, Inc. investor presentation 9 10-16 highlights reduced
Innovative PSA Testing Technologies and Emerging Markets
Innovative PSA Testing Technologies and Emerging Markets
Innovative AFP Testing Technologies and Emerging Markets
Innovative AFP Testing Technologies and Emerging Markets
IMERA Business Plan Sep 2023 Enterprise AI Event.pptx.pdf
IMERA Business Plan Sep 2023 Enterprise AI Event.pptx.pdf
Innovation in medical device and diagnostic industry at India Leadership Conc...
Innovation in medical device and diagnostic industry at India Leadership Conc...
Recently uploaded
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24
ppt-namibia-worldeconomy-standardbank.ppt
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
Methanex Investor Presentation - April 2024
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUES
Mutual funds are investment vehicles that pool money from multiple investors to purchase a diversified portfolio of stocks, bonds, or other securities. They are managed by professional portfolio managers or investment companies who make investment decisions on behalf of the fund's investors.
Cleades robinson:The Diplomat is Blue
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
一比一原版(UW毕业证)华盛顿大学毕业证成绩单专业办理
UW毕业证原版定制【微信：176555708】【华盛顿大学毕业证成绩单-学位证】【微信：176555708】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
学历顾问：微信：176555708
快速办理(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证录取通知书一模一样
学校原件一模一样【微信：741003700 】《(CUBoulder毕业证书)科罗拉多大学博尔德分校毕业证》【微信：741003700 】学位证，留信认证（真实可查，永久存档）原件一模一样纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原。
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
【主营项目】
一.毕业证【q微741003700】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【q/微741003700】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
Recently uploaded (14)
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Understanding-the-E-Way-Bill-A-Digital-Transformation-in-Logistics.pptx
Osisko Development - Investor Presentation - June 24
Osisko Development - Investor Presentation - June 24
Mandalay Resouces June 2024 Investor Relations PPT
Mandalay Resouces June 2024 Investor Relations PPT
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUES
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUES
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdf
Collective Mining | Corporate Presentation - June 2024
Collective Mining | Corporate Presentation - June 2024
OUI Medical Pitch 21-2-2023 copy.pptx
- 1. March 4, 2023 (C) Copyright 2021 1
- 2. Oui Medical Inc 2 SCOPE Peek Inside Body Cavity Dr Antoine – 1853 Transformed Medicine 250 Million procedures yearly 10 Types of Scope SCOPE
- 3. March 4, 2023 (C) Copyright 2021 3 Scope for Abdominal Cavity MISSION VISION Make Endoscopy Accessible & Safe
- 4. March 4, 2023 (C) Copyright 2021 4 Surgery is required to peek inside abdomen Laparoscopy Or Laparotomy • Admission, Anesthesia & Surgery • Painful, Inconvenient ,50000 $ PROBLEM
- 5. March 4, 2023 (C) Copyright 2021 5 Single use & Portable SOLUTION Worlds First Scope to peek inside abdomen using local anesthesia
- 6. March 4, 2023 (C) Copyright 2021 6 SOLUTION • Ambulatory Procedure • Local Anesthesia • Painless, Convenient $ 6000
- 7. March 4, 2023 7 MULTIPLE APPLICATIONS • Cancer Care • Women's Health • Emergency Care • Peri-Operative Care • Future Applications
- 8. March 4, 2023 (C) Copyright 2021 8 DISRUPTIVE TECHNOLOGY REUSABLE DISPOSABLE SINGLE USE $ 60000 + Maintenance $ 20000 + $ 2000+ Maintenance $ 2000 Bulky Portable Portable Sterilization Reduces cross infection Eliminates cross infection CAGR 8% CAGR 16% High adoption rate
- 9. March 4, 2023 (C) Copyright 2021 9 MARKET SIZE • TAM - $ 40 Bill Endoscopy globally • SAM - $ 4 Bill Single specialty scope • SOM - US $ 500 MM Single specialty scope US • Growth 8% CAGR • PATENT PENDING • NOVEL • PROPRIETARY TECHNOLOGY COMPETITION
- 10. March 4, 2023 (C) Copyright 2021 10 • Single Organ – Colon • 60 MM Colonoscopy Yearly • Abdomen – 10 Major Organs • Multiple Compelling Applications OPPORTUNITY 500K Procedures X $2000 = $1 Bill Revenue
- 11. March 4, 2023 (C) Copyright 2021 11 ASK $ 7 Million –Product to Series A FDA Breakthrough Device Pathway Device Ready Cadaver Study IRB Clearance Completed Q1 Q2 Q3 Q5 Clinical Study 510 K New CPT Code Q7 Simultaneous Regulatory Approval in EU & Asia
- 12. March 4, 2023 (C) Copyright 2021 12 GO TO MARKET & EXIT • 20 LARGE OEMS Midcap some Large cap • POTENTIAL PARTNERS Leverage Global Marketing & Distribution • NEW PRODUCTS Leverage disruptive tech
- 13. March 4, 2023 (C) Copyright 2021 13 PARTNERS Digital Imaging Supply medical grade camera Product Development & Contract manufacturing Guidance Seed Investment & Mentoring
- 14. March 4, 2023 (C) Copyright 2021 14 Founder & CEO Surgeon • Laparoscopic & Bariatric Surgeon • 15 Years experience with Scopes • Entrepreneur • Inventor Dr Adarsh M Patil MD TEAM Co Founder Hrishikesh Gadagkar Engineer • 30 Years of MedTech experience • Product development • Regulatory Landscape
- 15. March 4, 2023 (C) Copyright 2021 15 THANK YOU Paradigm shift in Endoscopy www.Oui-Medical.com ap@Oui-Medical.com